Paediatric Subjects - Special Survey

This study has been completed.
Information provided by:
Novo Nordisk A/S Identifier:
First received: February 15, 2012
Last updated: February 20, 2012
Last verified: February 2012

February 15, 2012
February 20, 2012
December 2003
October 2009   (final data collection date for primary outcome measure)
  • Response rate assessed by the investigator: Ability or failure to achieve expected glycaemic control [ Time Frame: Year 1 ] [ Designated as safety issue: No ]
  • HbA1c (glycosylated haemoglobin) [ Time Frame: Year 1 ] [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • Hypoglycaemic events [ Time Frame: Year 1 ] [ Designated as safety issue: No ]
  • Adverse Events [ Time Frame: Year 1 ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Paediatric Subjects - Special Survey
Special Survey for Paediatric Subjects
This study is conducted in Japan. The aim of this study is to collect safety and efficacy data when using insulin aspart in children with diabetes under normal clinical practice conditions.
Not Provided
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients under 15 years of age with diabetes requiring insulin therapy with no treatment history of insulin aspart (NovoRapid®)
  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
Drug: insulin aspart
Prescribed by the physicians as a result of normal clinical practice
Insulin aspart users
Intervention: Drug: insulin aspart
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2009
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with diabetes requiring insulin therapy

Exclusion Criteria:

  • Subjects who had treatment history of insulin aspart
up to 15 Years
Contact information is only displayed when the study is recruiting subjects
Public Access to Clinical Trials, Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Masayuki Senda Novo Nordisk Pharma Ltd.
Novo Nordisk A/S
February 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP